10X GENOMICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.35 USD | -0.83% |
|
-6.41% | -51.23% |
| Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
| Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
Financials (USD)
| Sales 2024 * | 678M | Sales 2025 * | 790M | Capitalization | 3.29B |
|---|---|---|---|---|---|
| Net income 2024 * | -188M | Net income 2025 * | -114M | EV / Sales 2024 * | 4.37 x |
| Net cash position 2024 * | 324M | Net cash position 2025 * | 366M | EV / Sales 2025 * | 3.7 x |
| P/E ratio 2024 * |
-17.4
x | P/E ratio 2025 * |
-29.8
x | Employees | 1,259 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on 10x Genomics, Inc.
More recommendations
More press releases
| 1 day | -0.79% | ||
| 1 week | -10.45% | ||
| Current month | -26.51% | ||
| 1 month | -24.00% | ||
| 3 months | -34.71% | ||
| 6 months | -30.81% | ||
| Current year | -50.71% |
1 week
26.75
29.45
1 month
26.7538.49
Current year
26.7555.96
1 year
26.7563.57
3 years
23.81208.99
5 years
23.81208.99
10 years
23.81208.99
| Managers | Title | Age | Since |
|---|---|---|---|
Serge Saxonov
FOU | Founder | 47 | 12-07-01 |
Ben Hindson
FOU | Founder | 49 | 12-07-01 |
Justin McAnear
DFI | Director of Finance/CFO | 49 | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Stuelpnagel
CHM | Chairman | 66 | 13-07-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-03-25 |
Mathai Mammen
BRD | Director/Board Member | 57 | 17-08-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 27.26 | -1.16% | 801 295 |
| 24-04-23 | 27.58 | -0.79% | 1,991,587 |
| 24-04-22 | 27.8 | -0.50% | 1,792,088 |
| 24-04-19 | 27.94 | -3.49% | 2,078,467 |
| 24-04-18 | 28.95 | -0.72% | 2,956,118 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Calendar
2024-04-30
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.58
USD
Average target price
52.29
USD
Spread / Average Target
+89.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.71% | 3.29B | |
| +0.80% | 12.82B | |
| -12.75% | 7.4B | |
| +2.81% | 5.47B | |
| -1.37% | 4.51B | |
| +3.89% | 4.42B | |
| +9.29% | 2.66B | |
| -15.10% | 2.07B | |
| -2.82% | 1.68B | |
| -14.72% | 1.66B |
- Stock Market
- Equities
- TXG Stock
